| scholarly article | Q13442814 |
| P50 | author | John Radford | Q42388605 |
| Andrew M Evens | Q49238133 | ||
| P2093 | author name string | Joshua T Cohen | |
| Peter Johnson | |||
| Ralph M Meyer | |||
| David C Hodgson | |||
| Kara M Kelly | |||
| Sharon M Castellino | |||
| Susan K Parsons | |||
| Tara O Henderson | |||
| Michael J Kelly | |||
| Frank G Keller | |||
| John Raemaekers | |||
| Anita J Kumar | |||
| Tobi J Henzer | |||
| P2860 | cites work | Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma | Q24632704 |
| Health-related quality of life in Hodgkin lymphoma: a systematic review | Q26740480 | ||
| The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease | Q26858893 | ||
| Second malignant neoplasms and cardiovascular disease following radiotherapy | Q26864522 | ||
| Second solid cancers after radiation therapy: a systematic review of the epidemiologic studies of the radiation dose-response relationship | Q26996120 | ||
| Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment. | Q30240299 | ||
| Decision analysis on alternative treatment strategies for favorable-prognosis, early-stage Hodgkin's disease | Q33767878 | ||
| Early-Stage Hodgkin's Lymphoma | Q34136279 | ||
| Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy | Q34527116 | ||
| Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? | Q34543719 | ||
| Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease | Q34550216 | ||
| Pediatric Hodgkin lymphoma: trade-offs between short- and long-term mortality risks | Q34640709 | ||
| Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study | Q34667727 | ||
| Prospective medical assessment of adults surviving childhood cancer: study design, cohort characteristics, and feasibility of the St. Jude Lifetime Cohort study | Q34939208 | ||
| An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma. | Q35016354 | ||
| A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: reduction in normal tissue dose and second cancer risk | Q35741338 | ||
| Surveillance computed tomography imaging and detection of relapse in intermediate- and advanced-stage pediatric Hodgkin's lymphoma: a report from the Children's Oncology Group | Q36025958 | ||
| Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group. | Q36058273 | ||
| Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin's lymphoma--a report from the Children's Oncology Group | Q36212381 | ||
| Excess mortality from breast cancer 20 years after diagnosis when life expectancy is normal | Q36622724 | ||
| Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer | Q36673832 | ||
| A Comparative Evaluation of Normal Tissue Doses for Patients Receiving Radiation Therapy for Hodgkin Lymphoma on the Childhood Cancer Survivor Study and Recent Children's Oncology Group Trials | Q37211391 | ||
| Treatment of Hodgkin lymphoma: the past, present, and future. | Q37235019 | ||
| Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study | Q37246499 | ||
| ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma | Q37598106 | ||
| Health-state utility values in breast cancer. | Q37800481 | ||
| Comparison of direct and indirect methods of estimating health state utilities for resource allocation: review and empirical analysis | Q37962908 | ||
| Bulky mediastinal classical Hodgkin lymphoma in young women | Q38214102 | ||
| Evidence-based focused review of the role of radiation therapy in the treatment of early-stage Hodgkin lymphoma | Q38326059 | ||
| Current approaches in the management of low risk Hodgkin lymphoma in children and adolescents | Q38396485 | ||
| Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma. | Q38410659 | ||
| Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma. | Q38817696 | ||
| Risk of Second Cancer in Hodgkin Lymphoma Survivors and Influence of Family History | Q38850144 | ||
| Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma | Q38942343 | ||
| Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine | Q38953322 | ||
| Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification | Q43674377 | ||
| Late morbidity and mortality in patients with Hodgkin's lymphoma treated during adulthood. | Q44480851 | ||
| Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. | Q45221374 | ||
| Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group | Q46443817 | ||
| Chronic Conditions and Utility-Based Health-Related Quality of Life in Adult Childhood Cancer Survivors | Q47768485 | ||
| Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. | Q50985747 | ||
| Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes. | Q51621180 | ||
| Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma. | Q51732409 | ||
| Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children | Q57239656 | ||
| Long-Term Mortality of Women with a Diagnosis of Breast Cancer | Q57560496 | ||
| Early Positron Emission Tomography Response–Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial | Q62096483 | ||
| The impact of involved node, involved field and mantle field radiotherapy on estimated radiation doses and risk of late effects for pediatric patients with Hodgkin lymphoma | Q62096505 | ||
| Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma | Q80126344 | ||
| United States life tables, 2010 | Q85935776 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Hodgkin lymphoma | Q209369 |
| P304 | page(s) | 212-221 | |
| P577 | publication date | 2018-04-29 | |
| P1433 | published in | British Journal of Haematology | Q4970200 |
| P1476 | title | Early-stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long-term patient outcomes | |
| P478 | volume | 182 |
Search more.